Eli Lilly Faces Challenges with Weight Loss Drugs Amid Financial Uncertainty
TL;DR Summary
Eli Lilly's weight loss drugs, Zepbound and Mounjaro, have missed Wall Street sales estimates by nearly $900 million, causing an 8% drop in shares. Despite high demand and market success, inventory issues have been blamed for the shortfall. This mirrors similar challenges faced by competitor Novo Nordisk with its drugs Ozempic and Wegovy. Eli Lilly plans to market Zepbound directly to consumers to boost sales, while addressing concerns over knockoff drugs. Despite the setback, Eli Lilly's shares have risen over 50% this year.
- Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and Mounjaro Futurism
- Lilly Cuts Outlook After Obesity Drug Sales Post First Miss Yahoo Finance
- Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products Investors | Eli Lilly and Company
- Eli Lilly’s quarter was messy. What to do with the stock is more clear-cut CNBC
- Eli Lilly Earnings Have Wall Street Jittery on Zepbound Sales. What Comes Next. Barron's
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 3 min read
Condensed
79%
404 → 83 words
Want the full story? Read the original article
Read on Futurism